You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Daniel Geiger Every time Daniel publishes a story, you’ll get an alert straight to your inbox!

Compass is a clinical-stage biotechnology company focused on developing psychedelics-based drugs for neuropsychiatric disorders. The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s ...

The real-estate brokerage Compass announced on June 14 that it was laying off 10% of its employees. CEO Robert Reffkin addressed the layoffs in an emailed memo to staff viewed by Insider. He said the ...

Compass Inc. (NYSE:COMP) shares fell more than 12% while Anywhere Real Estate Inc. (NYSE:HOUS) jumped over 52% on Monday after the companies announced a $10 billion all-stock merger, including debt.

Compass Inc. stock (NYSE: COMP) has been experiencing significant pressure, having declined over 15% within the last week, while the S&P 500 only fell by 0.6%. The catalyst for this decline: Compass’s ...

The race is on for brokerages to capture clients in an incredibly difficult housing market, and Compass believes a new technology offering will give it an advantage. The brokerage on Monday launched ...

Compass cements its dominance in U.S. real estate brokerage with an all-stock acquisition of Anywhere Real Estate. The Anywhere deal more than doubles Compass' adjusted EBITDA and revenue base, ...